190 results on '"Apollonio, Benedetta"'
Search Results
2. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
3. P1211: TUMOR-ACTIVATED LYMPH NODE FIBROBLASTS SUPPRESS T CELL FUNCTION IN DIFFUSE LARGE B CELL LYMPHOMA
4. Editorial: Hallmark of cancer: avoiding immune suppression
5. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
6. Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications
7. Supplementary Figure 3 from In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
8. Supplementary Tables 1 - 2 from In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
9. Supplementary Figure 1 from In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
10. Supplementary Figure 2 from In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
11. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
12. Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration
13. Extracellular vesicles released by CD40/IL-4–stimulated CLL cells confer altered functional properties to CD4+ T cells
14. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8
15. Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter’s Trans-Formed DLBCL and Germinal Center B-Cells
16. Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives
17. Targeting B-cell anergy in chronic lymphocytic leukemia
18. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia
19. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
20. The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”, Clinical Perspectives and Therapeutic Opportunities
21. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models
22. Subclonal heterogeneity in chronic lymphocytic leukaemia: revealing the importance of the lymphoid tumour microenvironment
23. A novel Rag2−/−γc−/−-xenograft model of human CLL
24. Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
25. Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing
26. Abstract 3165: Stroma-immune landscape in lymphoma: new mechanisms of immunosuppression and therapeutic targeting
27. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1 /PD-1 immunotherapy
28. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
29. ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data
30. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
31. Author response: ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data
32. Immunocluster: A Computational Tool to Explore the Immune Profile and Cellular Heterogeneity of Hematological Diseases Using Liquid and Imaging Mass, and Flow Cytometry Data
33. ImmunoCluster: A computational framework for the non-specialist to profile cellular heterogeneity in cytometry datasets
34. Diffuse Large B-Cell Lymphoma Remodels the Fibroblastic Reticular Network That Acquires Aberrant Immunosuppressive Capabilities; Implications for the Regulation of Anti-Tumor Immunity in the Immuno-Oncology Era
35. B Cell Anergy Modulated by TLR1/2 and the miR-17 similar to 92 Cluster Underlies the Indolent Clinical Course of Chronic Lymphocytic Leukemia Stereotyped Subset #4
36. B Cell Anergy Modulated by TLR1/2 and the miR-17∼92 Cluster Underlies the Indolent Clinical Course of Chronic Lymphocytic Leukemia Stereotyped Subset #4
37. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy
38. Diffuse Large B-Cell Lymphoma (DLBCL) Tumor Cells Reprogram Lymphatic Fibroblasts into Cancer-Associated Fibroblasts (CAFs) That Contribute to Tumor Microenvironment (TME)-Driven Immune Privilege
39. CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse
40. Diffuse Large B-Cell Lymphoma (DLBCL) Tumor Cells Reprogram Lymphatic Fibroblasts into Cancer-Associated Fibroblasts (CAFs) That Contribute to Tumor Microenvironment (TME)-Driven Immune Privilege
41. Subclonal heterogeneity in chronic lymphocytic leukaemia: revealing the importance of the lymphoid tumour microenvironment
42. Exosomes and CAFs: partners in crime
43. Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line
44. Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line
45. Anergy in CLL: Moving Towards the Clinic
46. From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
47. B-Cell Anergy Underlies Indolent Clinical Behavior Of CLL Stereotyped Subset #4
48. In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
49. Extracellular vesicles released by CD40/IL-4–stimulated CLL cells confer altered functional properties to CD4+ T cells.
50. Targeting the LYN/HS1 Signaling Axis in Chronic Lymphocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.